UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 495

Sortiert nach

Determining the optimal dose in the development of anticancer agents

Nature reviews. Clinical oncology, 2014-05, Vol.11 (5), p.272-281

2014

Volltextzugriff (PDF)

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2012-01, Vol.30 (3), p.282-290

2012

Volltextzugriff (PDF)

(Pre‐)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor

The oncologist (Dayton, Ohio), 2010-01, Vol.15 (6), p.539-547

2010

Volltextzugriff (PDF)

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

Journal of clinical oncology, 2009-07, Vol.27 (19), p.3126-3132

2009

Volltextzugriff (PDF)

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial

The lancet oncology, 2012-10, Vol.13 (10), p.1045-1054

2012

Volltextzugriff (PDF)

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe

Cancers, 2020-08, Vol.12 (8), p.2313

2020

Volltextzugriff (PDF)

Pazopanib, a new therapy for metastatic soft tissue sarcoma

Expert opinion on pharmacotherapy, 2013-05, Vol.14 (7), p.929-935

2013

Volltextzugriff (PDF)

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review

European journal of cancer (1990), 2006-12, Vol.42 (18), p.3127-3139

2006

Volltextzugriff (PDF)

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

Cancer research (Chicago, Ill.), 2009-07, Vol.69 (13), p.5383-5391

2009

Volltextzugriff (PDF)

Interaction of Cisplatin with the Human Organic Cation Transporter 2

Clinical cancer research, 2008-06, Vol.14 (12), p.3875-3880

2008

Volltextzugriff (PDF)

Alternative drug formulations of docetaxel: a review

Anti-cancer drugs, 2007-02, Vol.18 (2), p.95-103

2007

Volltextzugriff (PDF)

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

Clinical cancer research, 2011-02, Vol.17 (3), p.406-415

2011

Volltextzugriff (PDF)

Abstract ED01-01: Successes and failures of targeted drug development in adult and pediatric sarcomas

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.ED01-01-ED01-01

Verweij, Jaap

2019

Volltextzugriff (PDF)

Individual patient data analysis to assess modifications to the RECIST criteria

European journal of cancer (1990), 2009-01, Vol.45 (2), p.248-260

2009

Volltextzugriff (PDF)

Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib

JNCI : Journal of the National Cancer Institute, 2006-12, Vol.98 (23), p.1739-1742

2006

Volltextzugriff (PDF)

CYP3A422 genotype and systemic exposure affect paclitaxel-induced neurotoxicity

Clinical cancer research, 2013-06, Vol.19 (12), p.3316-3324

2013

Volltextzugriff (PDF)

Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study

Journal of clinical oncology, 2007-07, Vol.25 (21), p.3144-3150

2007

Volltextzugriff (PDF)

Drug Insight: gastrointestinal stromal tumors (GIST)-the solid tumor model for cancer-specific treatment

Nature clinical practice. Oncology, 2008-02, Vol.5 (2), p.102-111

2008

Volltextzugriff (PDF)

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

Clinical cancer research, 2012-10, Vol.18 (20), p.5780-5787

2012

Volltextzugriff (PDF)

Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese

Journal of clinical oncology, 2007-10, Vol.25 (30), p.4707-4713

2007

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11)

Clinical cancer research, 2001-08, Vol.7 (8), p.2182-2194

2001

Volltextzugriff (PDF)

Complementary and Alternative Medicine During Cancer Treatment: Beyond Innocence

The oncologist (Dayton, Ohio), 2006-07, Vol.11 (7), p.732-741

2006

Volltextzugriff (PDF)

Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5795-5804

2005

Volltextzugriff (PDF)

1 – 25 von 495

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(472)
Mit Volltextzugriff
(425)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(373)
Science & Technology
(337)
Life Sciences & Biomedicine
(334)
Oncology
(265)
Biological And Medical Sciences
(202)
Medical Sciences
(202)
Female
(192)
Pharmacology. Drug Treatments
(176)
Male
(171)
Middle Aged
(171)
Adult
(162)
Aged
(156)
Antineoplastic Agents
(131)
Neoplasms - Drug Therapy
(111)
Chemotherapy
(92)
Tumors
(79)
Pharmacology & Pharmacy
(71)
Antineoplastic Agents - Pharmacokinetics
(64)
Antineoplastic Agents, Phytogenic - Pharmacokinetics
(61)
Camptothecin - Analogs & Derivatives
(61)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Determining the optimal dose in the development of anticancer agents

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(Pre‐)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe

Pazopanib, a new therapy for metastatic soft tissue sarcoma

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

Interaction of Cisplatin with the Human Organic Cation Transporter 2

Alternative drug formulations of docetaxel: a review

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

Abstract ED01-01: Successes and failures of targeted drug development in adult and pediatric sarcomas

Individual patient data analysis to assess modifications to the RECIST criteria

Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib

CYP3A422 genotype and systemic exposure affect paclitaxel-induced neurotoxicity

Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study

Drug Insight: gastrointestinal stromal tumors (GIST)-the solid tumor model for cancer-specific treatment

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese

Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11)

Complementary and Alternative Medicine During Cancer Treatment: Beyond Innocence

Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study

Suchergebnisse filtern